InvestorsHub Logo
Followers 51
Posts 3973
Boards Moderated 0
Alias Born 03/20/2014

Re: None

Wednesday, 01/24/2024 7:49:33 AM

Wednesday, January 24, 2024 7:49:33 AM

Post# of 465089
BMY paid 14b for a company offering a Muscarinic Receptor Agonist.

That receptor is in the Blarcamesine bag of tricks. How much is it worth when coupled with the S-1R receptor?

Anavex has the goods folks. Don't listen to the noise.

Alzheimer's
Rett Syndrome
Schizophrenia

Many more to follow.

While KarXT from Karuna Therapeutics (KRTX), a muscarinic M1 receptor agonist, demonstrated weak benefits on cognitive impairments in individuals with Schizophrenia,[2] ANAVEX®3-71’s dual-pharmacological action on SIGMAR1 and M1 muscarinic receptors is implicated in its pro-cognitive effects in murine Alzheimer’s disease models and demonstrates its potential to treat cognitive and behavioral deficits in neurological diseases by affecting protein homeostasis in the central nervous system.



https://www.anavex.com/post/anavex-life-sciences-reports-publication-of-anavex-3-71-in-clinical-journal-confirming-pharmacokinet

All my posts are my opinion only and shouldn’t be used for decisions regarding purchasing or selling.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News